2-(3-(3-硝基苯基)脲基)乙酸甲酯 | 446069-99-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(3-(3-硝基苯基)脲基)乙酸甲酯
• 英文名称: methyl 2-(3-(3-nitrophenyl)ureido)acetate
• 英文别名: [[(3-nitrophenyl)amino]carbonyl]aminoacetic acid methyl ester；methyl 2-[(3-nitrophenyl)carbamoylamino]acetate
• CAS: 446069-99-4
• 化学式: C₁₀H₁₁N₃O₅
• mdl: MFCD12488575
• 分子量: 253.214
• InChiKey: HFTCFXDCNLHWKH-UHFFFAOYSA-N

物化性质

• 沸点：
  380.1±42.0 °C(Predicted)
• 密度：
  1.409±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(3-(3-硝基苯基)脲基)乙酸甲酯 在 水 、 碳酸氢钠 作用下， 以 盐酸 、 丙酮 为溶剂， 反应 16.0h， 以to afford the title compound (4.4 g)的产率得到3-(3-氨基苯基)-2,4-咪唑啉二酮
  参考文献：
  名称：

  Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents

  摘要：

  本发明涉及一种通式（I）的嘧啶衍生物，作为激酶抑制剂，其制备以及它们作为治疗各种疾病的药物的用途。

  公开号：

  US20040186118A1
• 作为产物：
  描述：

  3-硝基苯异氢酸酯 、 甘氨酸甲酯盐酸盐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到2-(3-(3-硝基苯基)脲基)乙酸甲酯
  参考文献：
  名称：

  [EN] CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
  [FR] PYRIMIDINES INHIBITRICES DE CHK-, PDK- ET DE AKT, PRODUCTION ET UTILISATION DE CES COMPOSES COMME AGENTS PHARMACEUTIQUES

  摘要：

  这项发明涉及通式（I）的嘧啶衍生物作为激酶抑制剂，它们的生产以及它们作为治疗各种疾病的药物的用途。

  公开号：

  WO2004048343A1

文献信息

• [EN] CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] PYRIMIDINES INHIBITRICES DE CHK-, PDK- ET DE AKT, PRODUCTION ET UTILISATION DE CES COMPOSES COMME AGENTS PHARMACEUTIQUES
  申请人：SCHERING AG

  公开号：WO2004048343A1

  公开（公告）日：2004-06-10

  This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases.

  这项发明涉及通式（I）的嘧啶衍生物作为激酶抑制剂，它们的生产以及它们作为治疗各种疾病的药物的用途。
• CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
  申请人：Schering Aktiengesellschaft

  公开号：EP1565446A1

  公开（公告）日：2005-08-24
• US7504410B2
  申请人：——

  公开号：US7504410B2

  公开（公告）日：2009-03-17
• Identification of Potent and Novel α4β1 Antagonists Using in Silico Screening
  作者：Juswinder Singh、Herman van Vlijmen、Yusheng Liao、Wen-Cherng Lee、Mark Cornebise、Mary Harris、I-hsiang Shu、Alan Gill、Julio H. Cuervo、William M. Abraham、Steven P. Adams

  DOI：10.1021/jm020054e

  日期：2002.7.1

  The antigen alpha4beta1 (very late antigen-4, VLA-4) plays an important role in the migration of white blood cells to sites of inflammation. It has been implicated in the pathology of a variety of diseases including asthma, multiple sclerosis, and rheumatoid arthritis. We describe a series of potent inhibitors of alpha4beta1 that were discovered using computational screening for replacements of the peptide region of an existing tetrapeptide-based alpha4beta1 inhibitor (1; 4-[N'-(2-methylphenyl)-ureido]phenylacetyl-Leu-Asp-Val) derived from fibronectin. The search query was constructed using a model of 1 that was based upon the X-ray conformation of the related integrin-binding region of vascular cell adhesion molecule-1 (VCAM-1). The 3D search query consisted of the N-terminal cap and the carboxyl side chain of 1 because, upon the basis of existing structure-activity data on this series, these were known to be critical for high-affinity binding to alpha4beta1. The computational screen identified 12 reagents from a virtual library of 8624 molecules as satisfying the model and our synthetic filters. All of the synthesized compounds tested inhibit alpha4beta1 association with VCAM-1, with the most potent compound having an IC50 of 1 nM, comparable to the starting compound. Using CATALYST, a 3D QSAR was generated that rationalizes the variation in activities of these alpha4beta1 antagonists. The most potent compound was evaluated in a sheep model of asthma, and a 30 mg nebulized dose was able to inhibit early and late airway responses in allergic sheep following antigen challenge and prevented the development of nonspecific airway hyperresponsiveness to carbachol. Our results demonstrate that it is possible to rapidly identify nonpeptidic replacements of integrin peptide antagonists, This approach should be useful in identification of nonpeptidic alpha4beta1 inhibitors with improved pharmacokinetic properties relative to their peptidic counterparts.
• Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
  申请人：——

  公开号：US20040186118A1

  公开（公告）日：2004-09-23

  This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases

  本发明涉及一种通式（I）的嘧啶衍生物，作为激酶抑制剂，其制备以及它们作为治疗各种疾病的药物的用途。